Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-672 (recombinant porcine factor VIII) for serious bleeding in acquired hemophilia A (Japan)
jRCT2051200066Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of susoctocog alfa in acquired haemophilia (AH), sponsored by Takeda. Primary endpoint: Percentage of participants with severe bleeding episodes who demonstrated response to TAK-672 therapy at 24 hours after initiation. Started Apr 2021; status: completed.
02
Drugs
susoctocog alfa
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on jRCT2051200066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200066.